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Objectives: Defining perioperative mortality as death that occurs within 30 days of surgery may under-
estimate ‘true’ mortality among patients undergoing hepatic resection. To better define perioperative
mortality, trends in the risk for death during the first 90 days after hepatectomy were assessed.
Methods: Surveillance, Epidemiology and End Results (SEER) Medicare data were used to identify 2597
patients who underwent hepatic resection during 1991–2006. Data on their clinicopathological charac-
teristics, surgical management and perioperative mortality were collected and survival was assessed at
30, 60 and 90 days post-surgery.
Results: Overall, 5.7% of patients died within the first 30 days. Postoperative mortality at 60 and 90 days
were 8.3% and 10.1%. In-hospital mortality after hepatic resection was greater among patients with
hepatocellular carcinoma (HCC) than among those with colorectal liver metastases (CRLM) (8.9% and
3.8%, respectively; P < 0.001). In CRLM patients, mortality increased from 4.3% at 30 days to 8.4% at 90
days, whereas mortality in HCC patients increased from 9.7% at 30 days to 15.0% at 90 days (both P <
0.05). Patients with HCC were twice as likely as CRLM patients to die within 30 days [odds ratio (OR)
2.03], 60 days (OR = 1.74) and 90 days (OR = 1.71) (all P < 0.001). Differences in 30- and 90-day mortality
were greatest among HCC patients undergoing major hepatic resection (P < 0.05).
Conclusions: Reporting deaths that occur within a maximum of 30 days of surgery underestimates the
mortality associated with hepatic resection. Traditional 30-day definitions of mortality are misleading and
surgeons should report all perioperative outcomes that occur within 90 days of hepatic resection.
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Introduction
Hepatic resection, alone or in combination with ablative tech-
niques, has increased over the past decade in patients with
primary hepatic or secondary metastatic lesions.1–4 In the USA,
the two most common indications for hepatic resection of a
malignant lesion are hepatocellular carcinoma (HCC) and col-
orectal liver metastasis (CRLM).3 Improvements in patient risk
factor modification, operative techniques and perioperative man-
agement have resulted in perioperative mortality rates of <1% in
high-volume hepatobiliary centres5 and 5–10% in population-
based analyses using administrative data.4 Traditionally, patient
mortality at 30 days has been used as a benchmark to assess the
quality of both hospital and surgeon performance in virtually all
major surgical procedures, including hepatic resection. As hepa-
tobiliary surgeons continue to expand the pool of operable can-
didates by using techniques such as resection combined with
ablation,6 portal vein embolization7 and two-stage hepatectomy,8
the potential risk for postoperative hepatic insufficiency and
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therefore late mortality increases. Mortality associated with
hepatic insufficiency may not be accurately captured in traditional
30-day measures of mortality because of the variance of hepatic
parenchymal regeneration after resection, which depend on
several factors, including the presence of underlying disease such
as cirrhosis or steatohepatitis.9
Most reports on mortality following hepatectomy for HCC or
CRLM come from large, single-institution series.1,10–15 Clinical risk
factors in patients with HCC often differ from those in patients
with CRLM, which makes it difficult to interpret data from studies
that report aggregate institutional perioperative mortality. In
addition, data from ‘centres of excellence’ may be subject to refer-
ral and reporting bias. Large, population-based studies assessing
the patterns of care and mortality in patients undergoing hepate-
ctomy have been limited by the use of only administrative data-
bases such as the National Inpatient Sample (NIS) and have
included patients without an oncological reason for hepatic resec-
tion.3,4,16,17 By contrast, the Surveillance, Epidemiology and End
Results (SEER) Cancer Registry provides patient- and primary
tumour-specific data, information about the utilization of perio-
perative services and data on patient outcomes. When SEER data
are linked with Medicare data, detailed claims-derived data on the
provision of services to beneficiaries become available, which
allows for better risk-adjusted analyses. In turn, the use of the
linked SEER–Medicare database allows for a more accurate exami-
nation of procedure utilization and patient outcomes that can
more readily be extrapolated to the US population at large.18 The
objective of the current study was to evaluate traditional 30-day
mortality relative to 90-day mortality. Specifically, its goal was to
quantitate the potential relative under-reporting of hepatectomy-
associated mortality by assessing the incremental increase in mor-
tality noted at 90 days in a cohort of patients with CRLM or HCC
within a SEER–Medicare linked dataset over a 16-year period. The
study hypothesis presumed that the inclusion of perioperative
deaths occurring up to 90 days following surgery would provide a
more accurate estimate of hepatectomy-associated mortality in
the perioperative period.
Materials and methods
Data source
Prospectively collected data from the linked SEER–Medicare data-
base were utilized. Taken together, these data represent the linking
of two large, population-based sources of data and provide
detailed information about Medicare beneficiaries with cancer.
The SEER database is maintained by the National Cancer Institute
(NCI)19 and its characteristics have been well described in prior
reports.20 The SEER programme of cancer registries collects clini-
cal, demographic and cause-of-death information for persons
with cancer. The SEER–Medicare data represent a linking of SEER
data to Medicare claims data for health care services covered from
the time of Medicare eligibility until death.21 These linked data are
available from 1991 and the SEER–Medicare database has success-
fully matched data for 93% of individuals aged 65 years at the
time of primary cancer diagnosis to their Medicare enrolment
files. Available data include information on the original surgical
resection in addition to any perioperative procedural interven-
tions in either inpatient or outpatient settings around the time of
the operation.
Case definitions
All Medicare-enrolled patients aged 65 years who were diag-
nosed with incident malignant primary colorectal adenocarci-
noma or HCC between 1991 and 2006 were evaluated for
inclusion. Patients with colorectal adenocarcinoma (CRC) or
HCC were identified according to International Classification of
Diseases for Oncology (ICD-O-3) topography, behaviour and his-
tology codes.22 Patients with CRC were included if they had topog-
raphy codes representative of primary tumours located in the
caecum, ascending colon, hepatic flexure, transverse colon, splenic
flexure, descending colon, sigmoid colon, large intestine, not oth-
erwise specified, rectosigmoid junction or rectum, as well as a
code indicative of malignant behaviour. For patients with CRC,
histology codes were selected to identify only patients with adeno-
carcinoma; patients with other histology codes (such as for carci-
noid histology, etc.) were excluded. A gastrointestinal pathologist
at Johns Hopkins Hospital (RAA) reviewed all histology codes to
determine which codes were relevant to CRC or HCC. Patients
with primary CRC and hepatic metastases were identified using
an established algorithm23 that employed the ICD, 9th Revision,
Clinical Modification (ICD-9-CM) diagnosis and procedure
codes and Current Procedural Terminology (CPT) codes for
malignant neoplasm of liver, secondary malignant neoplasm of
liver, hepatectomy and ablation of liver lesion or tissue. Patients
who underwent only ablations of CRLM or HCC were excluded
from this analysis. The study cohort included only patients
enrolled in both Medicare Parts A and B who were not enrolled in
a managed care plan during the study period. The SEER–Medicare
datasets for HCC and CRLM patients were combined for analysis.
Outcome and predictor variables
Previous studies have demonstrated the validity of Medicare
billing codes to assess a wide range of outcomes.24 Information on
age, gender, race, marital status and geographic region were
obtained from the SEER portion of the database. Variables were
transformed into categorical and indicator variables where appro-
priate. The Elixhauser Comorbidity Index, a comprehensive set of
30 comorbidity measures, was used to identify and adjust for
comorbid conditions.25–29 Comorbid diagnoses related to the
patient’s admission diagnosis (e.g. metastatic cancer), as well as
any comorbid condition with a frequency of <5, were excluded so
that a total of 20 comorbidities remained for analysis.
Statistical analyses
Median values with ranges were used to describe continuous data;
discrete variables were displayed as totals and frequencies. Cells
with fewer than 11 patients per variable cell were re-labelled as
474 HPB
HPB 2011, 13, 473–482 © 2011 International Hepato-Pancreato-Biliary Association
‘<11 (<X.x%)’ in compliance with the NCI regulation for report-
ing of SEER–Medicare data. Univariate comparisons were
assessed using the two-sample Student’s t-test or the Mann–
Whitney U-test for continuous variables and the chi-squared test
for dichotomous and categorical variables where appropriate. For
the purposes of analysis, the distribution of the total number of
comorbid conditions per patient was transformed into a categori-
cal variable representing either up to two comorbidities or more
than two comorbidities. Cumulative event rates were calculated
using the method of Kaplan and Meier30 and survival curves were
compared using the log-rank test. Survival time was calculated
from the date of the liver-directed operation to the time of interest
(e.g. 30 days or 90 days). In-hospital death was defined as patient
survival less than the total length of hospital stay after the liver-
directed operation. Multivariate logistic regression models were
constructed for patients who died within 30 days and within 90
days of surgery. In order to identify variables for inclusion in the
multivariate model, variables were selected using a univariate sig-
nificance of P < 0.25 in combination with important clinical vari-
ables and confounders. The Hosmer–Lemeshow goodness-of-fit
test and a receiver operating characteristic (ROC) curve were used
to evaluate the model’s performance and discriminative ability.
Significance levels were set at P < 0.05; all tests were two-sided. All
statistical analyses were performed using spss Version 18.0 (SPSS,
Inc., Chicago, IL, USA).
Results
Characteristics of the entire cohort
The demographic and clinical characteristics of the patient cohort
are outlined in Table 1. In total, 2597 patients were identified for
analysis. The majority of patients had CRLM (n = 1903, 73.3%)
rather than HCC (n = 694, 26.7%). The median number of
Table 1 Demographic, clinical, and operative characteristics of patients with colorectal liver metastasis (CRLM) or hepatocellular carcinoma
(HCC) undergoing hepatectomy during 1991–2006
Variable Total, n (%) CRLM, n (%) HCC, n (%) P-valuea
(n = 2597) (n = 1903) (n = 694)
Demographics
Median age at hepatectomy, years (range) 73.0 (65–98) 73.0 (65–98) 73.0 (65–92) 0.018
Male 1423 (54.8) 973 (51.1) 450 (64.8) <0.001
White race 2073 (79.8) 1624 (85.3) 449 (64.7) <0.001
Married 1684 (64.8) 1221 (64.2) 463 (66.7) 0.228
Urban 2407 (92.7) 1756 (92.3) 651 (93.8) 0.186
Primary tumour characteristics
Grade
Well-differentiated 292 (11.2) 119 (6.3) 173 (24.9) <0.001
Moderately differentiated 1533 (59.0) 1285 (67.5) 248 (35.7) <0.001
Poorly differentiated 499 (19.2) 396 (20.8) 103 (14.8) <0.001
Undifferentiated 36 (1.4) 18 (0.9) 18 (2.6) 0.001
Unknown 237 (9.1) 85 (4.5) 152 (21.9) 0.001
Elixhauser comorbidities
Median number of comorbidities (SD) 2.0 (1.9) 2.0 (1.8) 3.0 (2.0) <0.001
Operative details
Year of hepatectomy
1991–2000 1320 (50.8) 1012 (53.2) 308 (44.4) <0.001
2001–2006 1277 (49.2) 891 (46.8) 386 (55.6) <0.001
Hepatectomy alone 2295 (88.4) 1696 (89.1) 599 (86.3) 0.048
Hepatectomy and ablation 302 (11.6) 207 (10.9) 95 (13.7) 0.048
Type of hepatic resection
Partial hepatectomy only (wedge) 1551 (59.7) 1242 (65.3) 309 (44.5) <0.001
Hemihepatectomy 1046 (40.3) 661 (34.7) 385 (55.5) <0.001
Extended hepatectomy 117 (4.5) 66 (3.5) 51 (7.3) <0.001
Median length of stay, days (SD) 7.0 (8.5) 7.0 (7.4) 8.0 (11.1) 0.080
aAll statistical tests were performed with 1 degree of freedom (d.f.)
SD, standard deviation
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Elixhauser medical comorbidities was 2.0 (range: 0–11). The most
common medical comorbidities were cardiac arrhythmias (n =
564, 21.7%), peripheral vascular disorders (n = 338, 13.0%) and
congestive heart failure (n = 319, 12.3%). Out of the entire cohort,
49.2% of patients (n = 1277) underwent hepatectomy during
2001–2006 and the majority of patients underwent hepatectomy
alone (n = 2295, 88.4%). The use of combined hepatectomy +
ablation was restricted to 11.6% of the overall patient cohort (n =
302). In terms of the type of hepatic resection, 40.3% (n = 1046)
of patients were managed with a hemihepatectomy, whereas an
extended hepatectomy was utilized in 4.5% of patients (n = 117).
The median overall length of stay following the operation was 7.0
days (range: 0–220 days).
Patient and primary tumour characteristics:
CRLM vs. HCC
Given the known clinicopathological differences between patients
with HCC and CRLM, the data were stratified by cancer histology
(Table 1). As expected, numerous differences emerged between
patients with HCC and those with CRLM. Importantly, patients
with HCC had a greater median number of medical comorbidities
(3.0; range: 0–10) compared to patients with CRLM (2.0; range:
0-11) (P < 0.001). Patients with HCC were more likely to have an
Elixhauser comorbidity indicating liver dysfunction than pati-
ents with CRLM (n = 309, 44.5% and n = 84, 4.4%, respectively;
P < 0.001).
Operative details: CRLM vs. HCC
Patients with HCC were more likely to have undergone hepatic
resection in the later years of the study compared with patients
with CRLM (n = 386, 55.6% and n = 891, 46.8% for years 2001–
2006; P < 0.001). A combined modality approach of hepatectomy
+ ablation was employed more frequently in patients with HCC
than those with CRLM (n = 95, 13.7% and n = 207, 10.9%, respec-
tively; P = 0.048). Whereas patients with CRLM more often under-
went a partial hepatectomy only (i.e. wedge resection) (n = 1242,
65.3% vs. n = 309, 44.5%), patients with HCC were more likely to
have undergone a hemihepatectomy (n = 385, 55.5% vs. n = 661,
34.7%) (all P < 0.001). There was no difference in the median
length of stay between patients with HCC and those with CRLM
(P = 0.080).
Perioperative mortality
Overall, in-hospital mortality among all patients was 5.2% (n =
135) (Table 2). Patients with HCC incurred more than twice the
in-hospital mortality suffered by patients with CRLM (8.9% vs.
3.8%; P < 0.001). There was no difference in 30- or 90-day mor-
tality with respect to the year of hepatectomy (both P > 0.05 for
1991–2000 compared with 2001–2006). Differences in death rates
between patients with CRLM and those with HCC varied greatly
at 30, 60 and 90 days (all P < 0.001). Overall, 148 deaths (5.7%)
occurred by 30 days and an additional 115 deaths (representing
43.7% of all deaths) occurred between 30 and 90 days. In the
CRLM patient group, 81 deaths (4.3%) occurred by 30 days and
169 (8.4%) occurred by 90 days (Fig. 1). Similarly, in patients with
HCC, 67 deaths (9.7%) occurred by 30 days and 104 (15.0%)
occurred by 90 days. For patients with CRLM, assessing deaths at
90 days increased the perioperative mortality rate by >50% (n = 81
to n = 169) (Fig. 2). There was a similar difference between mor-
tality rates at 30 and 90 days in HCC patients, which increased by
36% from 67 at 30 days to 104 at 90 days.
As shown in Fig. 2, the slope of the curves representing the
incremental risk for death was steepest for both HCC and CRLM
Table 2 Perioperative mortality in patients with operatively managed colorectal liver metastasis (CRLM) (n = 1903) or hepatocellular carci-
noma (HCC) (n = 694) who died at 30 days, 60 days or 90 days of the liver-directed operation
Variable Total, n (%) CRLM, n (%) HCC, n (%) P-valuea
(n = 2597) (n = 1903) (n = 694)
In-hospital mortality 135 (5.2) 73 (3.8) 62 (8.9) <0.001
Death at 30 days 148 (5.7) 81 (4.3) 67 (9.7) <0.001
Death at 60 days 215 (8.3) 128 (6.7) 87 (12.5) <0.001
Death at 90 days 263 (10.1) 169 (8.4) 104 (15.0) <0.001
aAll statistical tests were performed with 1 degree of freedom (d.f.)
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patients within the first 30 days following hepatic resection (HCC
= 0.32% dead/day; CRLM = 0.14% dead/day). Of note, the risk for
death after hepatectomy for HCC and CRLM was 0.09% dead/day
at 30 days and 0.07% dead/day at 90 days. The curves for both
groups attained a relatively constant slope from day 90 that was
maintained at a relatively constant rate throughout the first year
(HCC = 0.08% dead/day; CRLM = 0.06% dead/day).
Factors associated with survival at 30 and 90 days
In assessing the entire study cohort, on univariate analysis the risk
for death at <30 days was associated with diagnosis of HCC, more
than two Elixhauser medical comorbidities, and resection 
hemihepatectomy (all P < 0.05). When the risk for death was
stratified by clinical diagnosis, among patients with CRLM the
risk for death within 30 days of surgery was associated with age
and an increased number of comorbidities. Similarly, among
patients with HCC, mortality within 30 days was associated with
increased age and male gender, but not with the number of Elix-
hauser comorbidities (Table 3). On multivariate logistic regres-
sion analysis (Table 4), the risk for death by 30 days remained
associated with a diagnosis of HCC [odds ratio (OR) 2.03, 95%
confidence interval (CI) 1.42–2.88; P < 0.001], more than two
Elixhauser medical comorbidities (OR = 1.61, 95% CI 1.14–2.27;
P = 0.007), and resection hemihepatectomy (OR = 1.53, 95% CI
1.08–2.16; P = 0.016). There was an incremental increased risk for
death by 90 days with a diagnosis of HCC (OR = 1.71, 95% CI
1.29–2.26; P < 0.001), more than two Elixhauser medical comor-
bidities (OR = 1.49, 95% CI 1.14–1.94; P = 0.003), and resection
hemihepatectomy (OR = 1.37, 95% CI 1.05–1.79; P = 0.019). After
controlling for other factors, patients with HCC were twice as
likely as those with CRLM to die within 30 days (OR = 2.03), 60
days (OR = 1.74) or 90 days (OR = 1.71) (all P < 0.001). Differ-
ences in 30- and 90-day mortality were greatest among HCC
patients undergoing major hepatic resection (P < 0.05) (Fig. 3).
Discussion
Even as recently as the 1980s, perioperative mortality associated
with hepatectomy was reported to be as high as 10–20%.10,11,31
Major hepatectomy was often associated with substantial blood
loss and varying degrees of hepatic insufficiency or failure. Over
the past several decades, however, mortality associated with
hepatic resection has decreased significantly.2,13,32,33 The reason for
this decrease in reported mortality is probably multi-factorial and
related, in part, to improvements in perioperative care, better
patient selection and improvements in operative techniques. Like
data reported for most other major surgical procedures,
hepatectomy-associated mortality has traditionally been reported
as any in-hospital death or death occurring within 30 days of the
surgical procedure. The reporting of death within this timeframe
was sufficient when the causes of perioperative death (e.g. sub-
stantial blood loss) transpired in a relatively short time. However,
operative techniques and methods to expand the number of
operative candidates (e.g. portal vein embolization, two-stage
hepatectomy, etc.) have changed, mandating a reconsideration of
what actually constitutes perioperative mortality. In parallel with
growing understanding of how liver insufficiency and liver failure
impact on mortality rates by causing ‘late’ deaths, there has been a
push toward the routine reporting of all deaths within 90 days of
hepatic resection. In fact, postoperative liver failure can occur in as
many as 15% of patients, ultimately accounting for >60% of
postoperative deaths.34 Although some major hepatobiliary
centres now routinely report 90-day mortality,34,35 operative mor-
tality is still frequently reported in the literature based on
in-hospital deaths only3 or events occurring within 30 days.1,36,37
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Perhaps more interestingly, despite the emerging consensus
among liver surgeons to report 90-day outcomes, there is a paucity
of data that actually quantify the potential relative underestima-
tion of hepatectomy-associated mortality caused by reporting 30-
rather than 90-day mortality. The current study is important
because it provides an empirical, quantitative benchmark of how
many hepatectomy-associated deaths are ‘missed’ by the reporting
of only in-hospital and 30-day outcomes. In addition, unlike
many previous studies, the SEER–Medicare dataset was utilized.
This allowed the reporting of more generalizable population-
based statistics, as well as disease-specific data regarding indica-
tions for hepatic resection (e.g. CRLM vs. HCC).
In the current study, overall hepatectomy-associated in-hospital
mortality was 5.2%, which is similar to rates previously reported
from other datasets such as the NIS.4,16 The NIS, however, may be
particularly poorly suited to estimate mortality associated with
hepatectomy as it contains only inpatient data and does not allow
mortality to be tracked longitudinally. As such, most population-
based data on hepatectomy-associated mortality are limited to the
inpatient setting. By contrast, the linked SEER–Medicare dataset
allows hepatectomy-associated mortality to be estimated over a
longer period of time from the index procedure. Accordingly,
in-hospital and 30-day mortality rates were found to be similar
(5.2% vs. 5.7%, respectively). Carroll et al.38 noted that in-hospital
and 30-day mortality rates after resection of pancreatic cancer
were similar, which suggested that comparisons of mortality rates
utilizing either of these metrics were acceptable. Perhaps of more
importance were findings regarding the incremental death events
noted between days 30 and 90 following hepatic resection. Spe-
cifically, of the 263 (10.1%) perioperative deaths in the cohort,
almost half (n = 115, 43.7%) occurred between days 31 and 90. As
such, 30-day mortality would have significantly underestimated
Table 4 Multivariate logistic regression analyses of factors associated with risk for death by 30 days compared with by 90 days in patients
undergoing liver-directed surgery for management of colorectal liver metastasis (CRLM) or hepatocellular carcinoma (HCC)
Prognostic factor Death at 30 days Death at 90 days
OR 95% CI P-value OR 95% CI P-value
HCC 2.03 1.42–2.88 <0.001 1.71 1.29–2.26 <0.001
Age >73 years 1.54 1.09–2.18 0.014 1.91 1.46–2.50 <0.001
>2 comorbidities 1.61 1.14–2.27 0.007 1.49 1.14–1.94 0.003
Resection  hemihepatectomy 1.53 1.08–2.16 0.016 1.37 1.05–1.79 0.019
All statistical tests were performed with 4 degrees of freedom (d.f.)
OR, odds ratio; 95% CI, 95% confidence interval
Survival from liver-directed operation, days
0
Patients at risk, n
CRLM and resection < hemihepatectomy 1242
CRLM and resection ≥ hemihepatectomy 661
HCC and resection < hemihepatectomy 309
HCC and resection ≥ hemihepatectomy 385
1195
627
285
342
1165
610
277
330
1142
602
272
318
1.00
0.95
0.90
0.85
0.80
0.75
30 60 90
P = 0.512
P = 0.046
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CRLM and resection < hemihepatectomy
CRLM and resection ≥ hemihepatectomy
HCC and resection < hemihepatectomy
HCC and resection ≥ hemihepatectomy
Figure 3 Survival in patients with colorectal liver metastasis (CRLM) or hepatocellular carcinoma (HCC) stratified by extent of liver resection
(n = 2597)
HPB 479
HPB 2011, 13, 473–482 © 2011 International Hepato-Pancreato-Biliary Association
the ‘true’ incidence of perioperative death associated with hepatic
surgery. Assessing deaths at 90 days increased the perioperative
mortality rate by >50% (from 4.3% at day 30 to 8.4% at day 90) in
CRLM patients and by 36% (9.7% at day 30 to 15.0% at day 90)
in HCC patients undergoing liver resection (Fig. 2). Rates of death
in patients with HCC or CRLM were also noted not to become
relatively constant until 90 days. In aggregate, these data strongly
suggest that a 30-day cut-off to report operative mortality for
hepatic resection is inappropriate as it underestimates the ‘true’
operative risk by about 50%.
Although most cancer care in the USA does not take place at
specialized cancer centres, the literature concerning perioperative
mortality following hepatectomy is most commonly derived from
large, single-institution series.1,34,35,39,40 The authors of the current
study have previously reported that actual population-based mor-
tality for liver resections may indeed be higher than rates reported
in the literature. In fact, the authors demonstrated that mortality
following liver surgery based on data derived from the NIS dataset
was 1.5 times higher than mortality reported from single-centre
experiences. The current work corroborates and expands on pre-
vious findings reported by its authors. Using the SEER–Medicare
dataset resulted in the demonstration of overall mortality rates of
5.2% at 30 days and 10.1% at 90 days. These mortality figures
stand in stark contrast with most mortality data published from
single-institution series, which have routinely reported the inci-
dence of postoperative deaths to be <2% or even zero.39,41–43
Although the reason for these disparate mortality figures is prob-
ably multi-factorial, the self-reporting of institutional data has
previously been shown to be susceptible to reporting bias.16,44,45
Population-based studies, such as the current study, are therefore
important as the data are more reflective of the mortality associ-
ated with hepatectomy at the national – rather than local or
regional – level.
In addition to urging the reporting of mortality data based on
90-day outcomes, the data presented in this report imply that such
data should be stratified by both operative indication and extent
of hepatic resection. Many single-institution series and
population-based studies have reported aggregate data on hepatic
resection, irrespective of either clinical diagnosis or extent of
hepatic resection.3,4,9,16,39,46 As demonstrated in the current study,
however, the clinical risk profiles of patients with HCC differed
significantly from those of patients with CRLM, resulting in an
almost two-fold increase in 30- and 90-day mortality (Fig. 2).
Depending upon the referral practices of a particular institution,
the case mix of patients undergoing hepatic resection for HCC
compared with those undergoing the same procedure for CRLM
may vary considerably across institutions. In addition, resection
hemihepatectomy was noted to be associated with an increased
risk for death by 90 days of about 40% (Fig. 3). As such, the
reporting of aggregate perioperative hepatectomy-associated
mortality data would seem to be inadequate and potentially mis-
leading. In an era scrutinized for optimal outcomes and charac-
terized by pay-for-performance policies,47 the present data
indicate that hepatectomy-associated mortality should be strati-
fied by both indication and type of hepatic surgery when compar-
ing different institutions.
The current study has several limitations. Although the SEER–
Medicare dataset allows for the examination of mortality in a
longitudinal manner, it does not provide data on the exact cause
of death. As such, data on the cause of death following hepatec-
tomy were lacking and it was not possible to evaluate the impact of
liver insufficiency or failure relative to other causes of death. The
objective of the study was, however, not to examine disease-
specific death, but, rather, to establish the relative differences in
overall 30- and 90-day mortality rates. In addition, because this
study utilized a dataset linked to Medicare, only patients aged65
years were included. In general, this limitation would not neces-
sarily seem to impact on the main findings and conclusions of the
study. However, it is possible that results from the current study
might have differed in a younger patient population with or
without similar comorbidities and this should be taken into
account in their consideration.
In conclusion, the traditional use of 30 days as a cut-off when
reporting mortality in patients undergoing hepatectomy for
malignancy is inadequate. Mortality based only on data known at
30 days is misleading and greatly underestimates actual periop-
erative mortality by up to 50%. Although the slope of the curve
representing the incremental risk for death is steepest within the
first 30 days following hepatic resection, it continues to rise for the
period between 30 and 90 days and does not attain a relatively
constant slope until after 90 days. In addition, given that patients
with HCC and CRLM empirically have differing clinicopathologi-
cal risk factors, institutional data on perioperative mortality
should be stratified by indication and the extent of resection.
Accurate information on perioperative mortality associated with
liver surgery is critical to gaining proper patient consent, as well as
for accurate risk assessment and stratification. Data from the
current study clearly and unequivocally establish 90-day mortality
as the standard metric for reporting mortality data following
hepatic resection.
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